… Author links open overlay panel Eric Plitman a b , Shinichiro Nakajima a c d e , Camilo de
la Fuente-Sandoval f g , Philip Gerretsen a b d e , M. Mallar Chakravarty h i , Jane Kobylianskii …

Kynurenic acid (KYNA) is an endogenous antagonist of N-methyl-D-aspartate and α7 nicotinic
acetylcholine receptors that is derived from astrocytes as part of the kynurenine pathway …

Glial disturbances are highly implicated in the pathophysiology of schizophrenia and may
be linked with glutamatergic dysregulation. Myo-inositol (mI), a putative marker of glial cells, …

Alterations in glutamatergic neurotransmission are implicated in the pathophysiology of
depression, and the glutamatergic system represents a treatment target for depression. To …

Abnormalities of the kynurenine (KYN) pathway may be implicated in the pathophysiology
of depression. However, the relationships between depression and each metabolite of the …

Background The glutamate (Glu) and gamma aminobutyric acid (GABA) hypotheses of
schizophrenia were proposed in the 1980s. However, current findings on those metabolite levels …

Importance Proton magnetic resonance spectroscopy (1H-MRS) studies indicate that altered
brain glutamatergic function may be associated with the pathophysiology of schizophrenia …

Antipsychotic drugs are the mainstay in the treatment of schizophrenia. However, one-third
of patients do not show adequate improvement in positive symptoms with non-clozapine …

Neuroimaging studies investigating patients with schizophrenia often report appreciable
volumetric reductions and cortical thinning, yet the cause of these deficits is unknown. The …

Background In terms of antipsychotic treatment response, patients with schizophrenia can
be classified into three groups: 1) treatment resistant to both non-clozapine (non-CLZ) …